Needham & Company affirms Aquinox Pharma (Nasdaq: AQXP) with a Buy rating and $25 price target after the company announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Aquinox Pharma (AQXP) Reports Negative KINSHIP Trial Data; Cowen Maintains Outperform November 3, 2015 2:22 PM Aquinox Pharma's (AQXP) Phase 2 KINSHIP Trial With AQX-1125 Fails to Demonstrate EfficacyNovember 3, 2015 6:36 AM Form 8-K AQUINOX PHARMACEUTICALS, For: Nov 02November 3, 2015 6:03 AM Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic DermatitisNovember 2, 2015 8:15 PM Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic DermatitisNovember 2, 2015 8:15 PM